Kiadis Pharma is a biopharmaceutical company based in Amsterdam, The Netherlands. We focus on the treatment of blood cancers and inherited blood disorders aiming to make bone marrow transplantations, a risky procedure that is often the last hope for patients, safer and more efficient. This means we have a passionate team that is dedicated to make a huge difference for patients. If you are up to the challenge and would like to be part of our team, we are currently making plans to expand our team in the second half of this year.
With the new growth of Kiadis and transition from an R&D company to a manufacturing company, we will need more QA specialists to strengthen our teams.
If you currently have experience as a QA officer, work within document review, if you are a QMS specialist or Compliance officer- we would like to meet and discuss our future plans with you.
The people that would be interesting to us would have:
- HBO/ B.Sc./ M.Sc. in Biotechnology, Chemistry or equivalent field.
- Experience in a similar role and international working environment within the pharmaceutical industry.
- Experience in GMP production/ Quality Control/ Manufacturing.
- Good command of the English language, written and verbal.
A chance for a new and challenging position in an innovative, fast growing, biotechnology company. Working in a fast-paced dynamic environment brings the opportunity to make your own mark within the organization. As we our currently unfolding our new QA department, you will get the chance to help develop and grow our new QA department.
You will be rewarded a competitive remuneration package, the opportunity for personal development and to contribute to make a huge difference for patients.
For further information, please contact us by phone at +31 (0)20 240 5 246 and ask for Caroline Vermeulen (Sr Specialist Talent Acquisition & Branding) or submit your resume and letter of interest through the application button.
Kiadis Pharma’s allodepleted T-cell immunotherapy product can make haploidentical hematopoietic stem cell transplantations (HSCT) safer and more effective. Based on the positive results from the Phase 2 trial, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101™ across the EU as an adjunctive treatment in HSCT for malignant disease. Kiadis Pharma is on track for potential (conditional) approval in Q4 2018 and market launch in 2019.
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients. Kiadis Pharma believes that its innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT), thereby meeting a significant unmet medical need with its products.More about Kiadis Pharma